Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
about
Companion diagnostics for the targeted therapy of gastric cancerComplementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancerHGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.Clinical impact of tumour biology in the management of gastroesophageal cancerIdentification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer.Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.Neuropilin-1 is associated with clinicopathology of gastric cancer and contributes to cell proliferation and migration as multifunctional co-receptors.Hypoxia/lncRNA-AK123072/EGFR pathway induced metastasis and invasion in gastric cancer.MET in gastric cancer--discarding a 10% cutoff ruleSerum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway.The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study.Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis.Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer.Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancerMET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.Update on Gastroesophageal Adenocarcinoma Targeted Therapies.Predictable factors for lymph node metastasis in early gastric cancer analysis of clinicopathologic factors and biological markers.Gene of the month: HGF.Chemotherapy for advanced gastric cancer: future perspective in Japan.The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2.Dynamic tracing for epidermal growth factor receptor mutations in urinary circulating DNA in gastric cancer patients.Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.Novel Targeted Therapies for Esophagogastric Cancer.Clinicopathologic and prognostic significance of human epidermal growth factor receptor in patients with gastric cancer: An updated meta-analysisFGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas.Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer.Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S-1 chemotherapy.Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma.A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.
P2860
Q26780298-535E230E-CE0B-47E9-9EEF-2CCC0F853181Q33888813-E4F1F33F-AAEA-419C-84D8-AF18F4AA6519Q33917507-38E9E422-9472-41A9-91F1-EA91C9C8BC19Q33922534-133E726C-BB03-4EC0-A376-DCC91F8565A1Q35032328-C3903BF2-ADA6-4BDB-900A-3F9AA3C7E64BQ35051995-4F2EA708-36C7-4E5A-B1BC-4EE1956C19ACQ35930811-DC152D49-578B-4B71-BBB7-5FB09BFE1A9DQ36069955-F401159F-5BA3-4EBC-BB5C-3EE812EE00EBQ36307708-8E00050F-AF65-4808-BB9B-7214820BBB5AQ36489958-9845BB58-3B8F-402D-89B6-987D16160BA6Q36492594-B80F2A6D-6F4C-4FD7-BF10-4FC26D2CA3E9Q36554574-DA624B0B-2CED-4C8C-B68E-C0307E97EB44Q36782629-733E4B80-016E-4008-AC2F-6A214CA2EF62Q37301868-F871EF36-0390-4DE7-B34B-F927F23BD032Q37302936-62EB1369-A253-4F58-A6F9-2755FFED45A8Q37342442-BA2807D6-0D49-49FE-9FCB-D8E76B776D91Q37567109-98E1ACEE-F917-4833-A863-17D7E0AFDD45Q37689064-C79257CB-CDC9-408C-AB36-DF87203882F4Q37705824-5CEC654F-4121-4786-AEB7-0948D92603A7Q38497265-12F35733-A364-40D3-AD25-36EDED9C2251Q38602669-C1FEA3DE-2038-4439-90FA-A7CF18560B2EQ38675350-7481ABB0-E232-4E15-9A00-1E6C32201E63Q38684349-BD62DF04-AA12-4690-AAF8-5AE882017C0EQ38687568-5185ED60-5549-4BE4-9A55-3BD809D6E4FCQ38806819-77B8CF42-7417-4B0F-9BF1-B1DC36920175Q38815071-091AD289-84D9-4CDD-8B8D-C63CF8C67543Q38824065-7B9443A1-1378-4737-9F0E-3CEC84A3BE9BQ38825712-9C76D54E-5C2A-4240-9102-90901B3FF05DQ38949788-4029BE74-EF2A-4F37-A80C-010C3B18DF89Q38951195-C7A56AC4-D572-4777-B356-37A9A213BB4CQ39038837-FCCD0FEA-D5C8-46D5-A27F-606490913836Q39171565-17129BB4-A444-4317-9CFD-8C72BEDC02C8Q40332121-5C6250DB-AA7F-42F0-92BF-DBE690453441Q40733626-1DC68416-8F74-4E69-9FEA-F2D399F3EDFDQ41693807-273EF205-CB7E-4DFD-9764-C4D1DDDE758DQ42717966-1EB65E38-6E93-4C20-9D7C-CCBF0E1616BFQ47552119-1222A9BD-0C98-4FDE-AF62-D75DCFBD46EBQ49639370-522B58EE-CA65-49D1-8C41-5F3171FFEE4AQ49961144-1FADA011-7DF0-4BD9-85CD-F912BD4C4B88Q52766440-D41E62D9-5D9E-4254-9C9D-1279B3A97D33
P2860
Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Expression profiles of HER2, E ...... s with gastric adenocarcinoma.
@en
Expression profiles of HER2, E ...... s with gastric adenocarcinoma.
@nl
type
label
Expression profiles of HER2, E ...... s with gastric adenocarcinoma.
@en
Expression profiles of HER2, E ...... s with gastric adenocarcinoma.
@nl
prefLabel
Expression profiles of HER2, E ...... s with gastric adenocarcinoma.
@en
Expression profiles of HER2, E ...... s with gastric adenocarcinoma.
@nl
P2093
P2860
P1433
P1476
Expression profiles of HER2, E ...... s with gastric adenocarcinoma.
@en
P2093
Akiko Kawano Nagatsuma
Atsushi Ochiai
Atsushi Ohtsu
Hirofumi Fujii
Masaki Aizawa
Takeshi Kuwata
P2860
P2888
P304
P356
10.1007/S10120-014-0360-4
P577
2014-03-14T00:00:00Z